Back to Results

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for hepatocellular carcinoma, metabolic liver diseases, and other chronic liver conditions in the United States. Its lead candidate, Rencofilstat, is designed to inhibit cyclophilin enzymes involved in protein folding, and preclinical studies have indicated potential effects on liver fibrosis, liver inflammation, liver tumor burden, and viral titers associated with HBV, HCV, and HDV. The company, formerly known as ContraVir Pharmaceuticals, Inc., adopted its current name in July 2019. Hepion Pharmaceuticals was incorporated in 2013 and is based in Morristown, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-HEPA
$0.059
33.6% Upside
Undervalued
—
—
—
Fair
—
—
—
0.0%
August 13, 2026
-0.6x
11.0x
—
1.31 M
868.826 K
0.0%
74.2%
-130.0
—
52.8%
Valuation • Fair Value

Hepion Pharmaceuticals Inc (OTC-HEPA) Fair Value by Valuation Model

Compare the primary fair value estimate for Hepion Pharmaceuticals Inc (OTC-HEPA) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.059

Estimated upside of 33.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.059

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Hepion Pharmaceuticals Inc (OTC-HEPA) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Hepion Pharmaceuticals Inc (OTC-HEPA)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Hepion Pharmaceuticals Inc (OTC-HEPA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Hepion Pharmaceuticals Inc (OTC-HEPA)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-130.0

Lower score that deserves closer risk review.

FCF / Net Income

52.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Hepion Pharmaceuticals Inc (OTC-HEPA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Hepion Pharmaceuticals Inc (OTC-HEPA)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Hepion Pharmaceuticals Inc (OTC-HEPA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Hepion Pharmaceuticals Inc (OTC-HEPA) Stock Forecast & Technical Outlook

Review Hepion Pharmaceuticals Inc (OTC-HEPA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Hepion Pharmaceuticals Inc (OTC-HEPA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Hepion Pharmaceuticals Inc (OTC-HEPA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Hepion Pharmaceuticals Inc (OTC-HEPA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Hepion Pharmaceuticals Inc (OTC-HEPA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Hepion Pharmaceuticals Inc (OTC-HEPA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Hepion Pharmaceuticals Inc (OTC-HEPA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Hepion Pharmaceuticals Inc (OTC-HEPA) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Hepion Pharmaceuticals Inc (OTC-HEPA) Stock FAQ

Quick answers about Hepion Pharmaceuticals Inc (OTC-HEPA) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.059
Estimated upside 33.6%
Valuation Rating
Undervalued
Estimated upside of 33.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Hepion Pharmaceuticals Inc (OTC-HEPA) is $0.059. This implies an estimated upside of 33.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 33.6% versus the current market price.

An analyst price target for Hepion Pharmaceuticals Inc (OTC-HEPA) is not currently available in the latest data file.

The current financial health read for Hepion Pharmaceuticals Inc (OTC-HEPA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Hepion Pharmaceuticals Inc (OTC-HEPA) is August 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Hepion Pharmaceuticals Inc (OTC-HEPA) is -0.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Hepion Pharmaceuticals Inc is 1.31 M.

The current enterprise value listed for Hepion Pharmaceuticals Inc is 868.826 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Hepion Pharmaceuticals Inc is OTC-HEPA, and the stock is listed on OTC Markets.

Hepion Pharmaceuticals Inc (OTC-HEPA) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Hepion Pharmaceuticals Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Hepion Pharmaceuticals Inc is 74.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)